Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases.

Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ.

Kidney Int. 2008 Mar;73(6):684-90. Review.

2.

CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.

Soos TJ, Meijer L, Nelson PJ.

Drug News Perspect. 2006 Jul-Aug;19(6):325-8. Review.

PMID:
16971968
3.

6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.

Xingi E, Smirlis D, Myrianthopoulos V, Magiatis P, Grant KM, Meijer L, Mikros E, Skaltsounis AL, Soteriadou K.

Int J Parasitol. 2009 Oct;39(12):1289-303. doi: 10.1016/j.ijpara.2009.04.005.

PMID:
19445946
4.

Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis.

Wang Y, Huang WC, Wang CY, Tsai CC, Chen CL, Chang YT, Kai JI, Lin CF.

Br J Pharmacol. 2009 Jul;157(6):1004-13. doi: 10.1111/j.1476-5381.2009.00284.x.

5.

Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones.

Power DP, Lozach O, Meijer L, Grayson DH, Connon SJ.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4940-4. doi: 10.1016/j.bmcl.2010.06.024.

PMID:
20621478
6.

Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P, Meijer L.

J Med Chem. 2004 Feb 12;47(4):935-46.

PMID:
14761195
7.

The CDK inhibitors in cancer research and therapy.

Cicenas J, Valius M.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1409-18. doi: 10.1007/s00432-011-1039-4. Review.

PMID:
21877198
8.

Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.

Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE.

Kidney Int. 2000 Aug;58(2):674-83.

9.

Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.

Medina M, Castro A.

Curr Opin Drug Discov Devel. 2008 Jul;11(4):533-43. Review.

PMID:
18600569
10.

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. Review.

PMID:
20698823
11.
12.

Progress in the evaluation of CDK inhibitors as anti-tumor agents.

McInnes C.

Drug Discov Today. 2008 Oct;13(19-20):875-81. doi: 10.1016/j.drudis.2008.06.012. Review.

PMID:
18639646
13.

The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy.

Palomo V, Perez DI, Gil C, Martinez A.

Curr Med Chem. 2011;18(20):3028-34. Review.

PMID:
21651477
14.

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

Canavese M, Santo L, Raje N.

Cancer Biol Ther. 2012 May;13(7):451-7. doi: 10.4161/cbt.19589. Review.

PMID:
22361734
15.

Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.

Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H.

J Immunol. 2008 Feb 1;180(3):1954-61.

16.

Cyclins and the cyclin-kinase system--their potential roles in nephrology.

Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, Marumo F.

Nephrol Dial Transplant. 1998 Aug;13(8):1913-6. Review.

17.

Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1-5, GSK-3) inhibitors.

Rochais C, Duc NV, Lescot E, Sopkova-de Oliveira Santos J, Bureau R, Meijer L, Dallemagne P, Rault S.

Eur J Med Chem. 2009 Feb;44(2):708-16. doi: 10.1016/j.ejmech.2008.05.011.

PMID:
18586356
18.

Glycogen synthase kinase-3--an overview of an over-achieving protein kinase.

Kockeritz L, Doble B, Patel S, Woodgett JR.

Curr Drug Targets. 2006 Nov;7(11):1377-88. Review.

PMID:
17100578
19.

Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.

Stone A, Sutherland RL, Musgrove EA.

Crit Rev Oncog. 2012;17(2):175-98. Review.

PMID:
22471707
20.
Items per page

Supplemental Content

Support Center